Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MoonLake Immunotherapeutics ( (MLTX) ) is now available.
On September 28, 2025, MoonLake Immunotherapeutics announced the week 16 results of its Phase 3 VELA-1 and VELA-2 trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The trials showed statistically significant improvements in primary and key secondary endpoints, although VELA-2 faced challenges due to unexpected placebo effects. Sonelokimab maintained a favorable safety profile, and the company plans to continue towards a week 52 readout and seek regulatory approval.
The most recent analyst rating on (MLTX) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on MoonLake Immunotherapeutics stock, see the MLTX Stock Forecast page.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.
To see Spark’s full report on MLTX stock, click here.
More about MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing advanced therapies for inflammatory diseases.
Average Trading Volume: 582,724
Technical Sentiment Signal: Buy
Current Market Cap: $3.98B
See more data about MLTX stock on TipRanks’ Stock Analysis page.